Abstract
Global concern about Alzheimer's disease (AD) is justified by its increasingly younger onset and significant economic burden. AD leads to neurodegeneration and cognitive decline, ultimately resulting in loss of autonomy. Against this background, the field of biomedical research has seen a surge of interest in the potential of carbon-based nanomaterials, mainly due to their ease of degradation and high biocompatibility. Carbon nanotubes (CNTs) have been extensively studied in AD, including developing biosensors, drug delivery systems, and molecular imaging. Here, we introduced the biosafety and biodegradability of CNTs, with a particular focus on their uptake and degradation in brain tissue. The utilization of CNT in the context of AD therapy can facilitate the advancement of control approaches regimens and ensure the clinical safety of patients. This is achieved through the employment of these nanotubes as carriers for the delivery of drugs to the central nervous system (CNS), the detection of neurotransmitters such as acetylcholine (Ach) and monoamines, the development of biosensors and molecular imaging materials, the inhibition of Aβ formation and the detection of phosphorylated tau proteins, the promotion of CNS regeneration, and the modulation of ion-associated AD.